Living to 120 is no longer science fiction. It’s quickly becoming one of the most ambitious investment frontiers of our time.Join me at the Global Longevity Summit this October. Use code BEYONDTOMORROW for 10% off your ticket: https://informaconnect.com/global-longevity-summit/In this Moonshot Special of Longevity Unpacked, I sit down with Will Harborne and Sebastian Brunemeier from LongGame Ventures. They’re not just talking about supplements or lifestyle hacks, they’re backing companies working on gene therapies, stem cell treatments, organ replacement, and even embryo selection.We also dig into why longevity biotech feels like crypto in 2012, what the “GLP1 of aging” might be, and the ethical questions that come with reshaping how long humans can live.📌 What You’ll Learn in This Episode:Why longevity biotech is at the same stage today as crypto was a decade agoHow cell therapy and gene therapy are already reversing disease and extending healthspanThe science of epigenetic reprogramming and Yamanaka factorsWhy cloning without consciousness could unlock unlimited organ replacementThe rise of embryo selection and what it means for the future of humanityThe coming GLP1 moment for longevity drugsHow AI and superintelligence will accelerate biotech breakthroughsThe demographic crisis of aging populations and how biotech can solve itThe ethical questions around immortality, consciousness, and equity of accessWhat Sebastian and Will believe the world could look like by 2040⏱ Timestamps0:00 Should we extend human lifespan?0:28 Introducing Sebastian Brunemeier & Will Harborne1:39 Why invest in longevity biotech now5:25 What counts as longevity biotech?7:11 Are we too early for radical life extension?10:04 Gene therapy, stem cells and real-world examples14:25 Germline immortality explained18:40 Gene delivery, viral vs non-viral vectors22:16 Replacement and cloning for organ growth29:38 What does it mean to be human?32:42 Embryo selection, polygenic scoring and ethics42:40 Whole brain emulation and mind uploading50:11 The low hanging fruit longevity drugs57:00 What will be the GLP1 of longevity1:04:03 How AI and superintelligence accelerate biotech1:06:17 The silver tsunami and economic impact1:13:05 Biological superintelligence and Homo Deus1:18:10 Will longevity tech only be for the rich1:21:59 Why small biotech will disrupt big pharma1:22:15 Advice for founders and investors entering longevity🎙 Hosted by Julian Issa📸 Instagram: @thebeyondtomorrowpodcast🌐 Website: www.beyondtomorrowpodcast.com📩 Email: [email protected]🎧 Subscribe on Spotify, Apple, and YouTube for more stories from the edge of what’s possible.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related